Blab Sports
Olympic Skier Bode Miller Arrested in Idaho on Psilocybin Possession Charges
Bode Miller, the former American alpine ski champion, was arrested on June 6, 2026, in eastern Idaho on charges of possessing psilocybin mushrooms. The incident occurred during a traffic stop in which Miller was cited for accelerating while passing another vehicle on a highway. According to a probable‑cause affidavit released by the Fremont County Sheriff's Office, the arresting officer found a white dispensary bag in Miller’s vehicle that contained 4.1 grams of psilocybin mushrooms. Miller was charged with two misdemeanor counts of possession of a Schedule I controlled substance.
Miller entered a plea of not guilty to the charges. He posted a $5,000 bond and was released from jail. In a statement posted to social media on the same day, Miller said, “I was pulled over for accelerating while passing another vehicle on a highway in Idaho. My friend, who was traveling with me, had a small amount of cannabis and a cannabis pipe in his possession which I was unaware of. We fully cooperated with the officer. I am hopeful the misdemeanor charges will be dropped once the facts are reviewed.” The statement did not address the mushrooms that were reportedly found.
Idaho treats psilocybin as a Schedule I controlled substance under state law, and the state maintains a strict no‑tolerance policy. Possession of any amount of a Schedule I drug can be charged as a misdemeanor and may carry up to one year in jail and a fine of up to $1,000. The state’s Uniform Controlled Substances Act, codified in Idaho Code § 37‑2705, lists psilocybin among substances that are prohibited.
The federal Controlled Substances Act also classifies psilocybin as a Schedule I drug, meaning it is considered to have no accepted medical use and a high potential for abuse. However, the legal landscape for psilocybin has been evolving. In 2023, Australia approved psilocybin for treatment‑resistant depression, and the United States is conducting late‑stage clinical trials for major depressive disorder and treatment‑resistant depression. President Donald Trump signed an executive order in 2021 that fast‑tracks the FDA’s review of psychedelic therapies, including psilocybin.
In states such as Colorado and Oregon, frameworks exist for supervised therapeutic use of psilocybin. Athletes who have experienced repeated head trauma are sometimes considered candidates for such treatments. Miller, who has spoken publicly about the physical toll of his racing career—including repeated head injuries—has not indicated any intention to seek psychedelic therapy.
The arrest has drawn attention to Idaho’s stringent drug laws. The state’s Office of Drug Policy has stated that it opposes the legalization of marijuana in any form other than specific FDA‑approved medications. Idaho remains one of the most restrictive states in the United States regarding cannabis and other controlled substances.
Miller’s case is still pending. The Fremont County Sheriff's Office has not announced any further action, and the court has not yet scheduled a hearing. Miller’s legal team has not released a statement beyond the plea entered. The Idaho Department of Justice has not issued a public comment.
The incident comes at a time when the broader conversation about psychedelic substances is gaining traction in medical and legal circles. While the federal government is exploring therapeutic applications, state laws such as Idaho’s continue to enforce strict penalties for possession.
For now, the outcome of Miller’s case will depend on the court’s review of the evidence presented by law enforcement and the defense. If the charges are dismissed, Miller may face no further legal consequences. If the charges are upheld, he could face up to a year in jail and a fine of up to $1,000, in addition to potential civil penalties.
The case also highlights the ongoing tension between evolving medical research on psychedelics and the existing legal frameworks that govern their possession and use. As the federal and state legal landscapes continue to shift, cases like Miller’s may serve as reference points for future policy discussions.
Until a court decision is made, the status of Miller’s legal situation remains unresolved. The public will continue to monitor developments as the case proceeds through the Idaho judicial system.
Miller entered a plea of not guilty to the charges. He posted a $5,000 bond and was released from jail. In a statement posted to social media on the same day, Miller said, “I was pulled over for accelerating while passing another vehicle on a highway in Idaho. My friend, who was traveling with me, had a small amount of cannabis and a cannabis pipe in his possession which I was unaware of. We fully cooperated with the officer. I am hopeful the misdemeanor charges will be dropped once the facts are reviewed.” The statement did not address the mushrooms that were reportedly found.
Idaho treats psilocybin as a Schedule I controlled substance under state law, and the state maintains a strict no‑tolerance policy. Possession of any amount of a Schedule I drug can be charged as a misdemeanor and may carry up to one year in jail and a fine of up to $1,000. The state’s Uniform Controlled Substances Act, codified in Idaho Code § 37‑2705, lists psilocybin among substances that are prohibited.
The federal Controlled Substances Act also classifies psilocybin as a Schedule I drug, meaning it is considered to have no accepted medical use and a high potential for abuse. However, the legal landscape for psilocybin has been evolving. In 2023, Australia approved psilocybin for treatment‑resistant depression, and the United States is conducting late‑stage clinical trials for major depressive disorder and treatment‑resistant depression. President Donald Trump signed an executive order in 2021 that fast‑tracks the FDA’s review of psychedelic therapies, including psilocybin.
In states such as Colorado and Oregon, frameworks exist for supervised therapeutic use of psilocybin. Athletes who have experienced repeated head trauma are sometimes considered candidates for such treatments. Miller, who has spoken publicly about the physical toll of his racing career—including repeated head injuries—has not indicated any intention to seek psychedelic therapy.
The arrest has drawn attention to Idaho’s stringent drug laws. The state’s Office of Drug Policy has stated that it opposes the legalization of marijuana in any form other than specific FDA‑approved medications. Idaho remains one of the most restrictive states in the United States regarding cannabis and other controlled substances.
Miller’s case is still pending. The Fremont County Sheriff's Office has not announced any further action, and the court has not yet scheduled a hearing. Miller’s legal team has not released a statement beyond the plea entered. The Idaho Department of Justice has not issued a public comment.
The incident comes at a time when the broader conversation about psychedelic substances is gaining traction in medical and legal circles. While the federal government is exploring therapeutic applications, state laws such as Idaho’s continue to enforce strict penalties for possession.
For now, the outcome of Miller’s case will depend on the court’s review of the evidence presented by law enforcement and the defense. If the charges are dismissed, Miller may face no further legal consequences. If the charges are upheld, he could face up to a year in jail and a fine of up to $1,000, in addition to potential civil penalties.
The case also highlights the ongoing tension between evolving medical research on psychedelics and the existing legal frameworks that govern their possession and use. As the federal and state legal landscapes continue to shift, cases like Miller’s may serve as reference points for future policy discussions.
Until a court decision is made, the status of Miller’s legal situation remains unresolved. The public will continue to monitor developments as the case proceeds through the Idaho judicial system.
